Akèy › Glomeruloskleroz fokal segmantè › Minnesota
Etid klinik pou Glomeruloskleroz fokal segmantè nan Minnesota
5 etid pou Glomeruloskleroz fokal segmantè ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- InterMed Consultants - Edina Clinic- Site Number : 8400019, Edina
Ap rekriteFaz 2
Laj 16 a 75 · Tout sèks · Mizajou Sep 23, 2026 · NCT06500702Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- University of Minnesota, Minneapolis
Ap rekrite
Jiska laj 21 · Tout sèks · Mizajou Aug 28, 2026 · NCT02235857Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- University of Minnesota, Masonic Children's Hospital, Minneapolis
Ap rekriteFaz 2
Laj 1 a 17 · Tout sèks · Mizajou May 12, 2026 · NCT05003986SLIT ABS: Study on Patients With Autoimmune Podocytopathy
- Mayo Clinic, Rochester
Ap rekrite
Laj 0 a 99 · Tout sèks · Mizajou Apr 8, 2026 · NCT07516964A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- University of Minnesota, Minneapolis
Ap rekriteFaz 3
Laj 12 a 80 · Tout sèks · Mizajou Feb 3, 2026 · NCT05183646Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.